The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome

Z Sayar, S Burke, P Mittal, H Cohen - Lupus, 2022 - journals.sagepub.com
Limited evidence exists to guide the management of recurrent thrombosis occurring despite
therapeutic anticoagulation in patients with thrombotic antiphospholipid syndrome (APS). In …

The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome

Z Sayar, S Burke, P Mittal, H Cohen - Lupus, 2022 - pubmed.ncbi.nlm.nih.gov
Limited evidence exists to guide the management of recurrent thrombosis occurring despite
therapeutic anticoagulation in patients with thrombotic antiphospholipid syndrome (APS). In …

The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome.

Z Sayar, S Burke, P Mittal, H Cohen - Lupus, 2022 - europepmc.org
Limited evidence exists to guide the management of recurrent thrombosis occurring despite
therapeutic anticoagulation in patients with thrombotic antiphospholipid syndrome (APS). In …

The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome.

Z Sayar, S Burke, P Mittal, H Cohen - Lupus, 2022 - search.ebscohost.com
Limited evidence exists to guide the management of recurrent thrombosis occurring despite
therapeutic anticoagulation in patients with thrombotic antiphospholipid syndrome (APS). In …

[HTML][HTML] The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome

Z Sayar, S Burke, P Mittal, H Cohen - Lupus, 2022 - ncbi.nlm.nih.gov
Limited evidence exists to guide the management of recurrent thrombosis occurring despite
therapeutic anticoagulation in patients with thrombotic antiphospholipid syndrome (APS). In …

The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome.

Z Sayar, S Burke, P Mittal, H Cohen - Lupus, 2022 - europepmc.org
Limited evidence exists to guide the management of recurrent thrombosis occurring despite
therapeutic anticoagulation in patients with thrombotic antiphospholipid syndrome (APS). In …